Mestinon, generically known as pyridostigmine, is a medication primarily used in the treatment of myasthenia gravis, a chronic autoimmune neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Pyridostigmine belongs to a class of drugs known as cholinesterase inhibitors, which work by improving communication between nerves and muscles, thereby increasing muscle strength. Mestinon is effective in alleviating symptoms such as difficulty swallowing, double vision, drooping eyelids, and muscle weakness. It is available in various forms, including tablets, extended-release tablets, and a syrup, allowing for flexibility in dosing to meet individual patient needs. While Mestinon significantly enhances the quality of life for those with myasthenia gravis, it is not a cure for the condition and must be taken regularly to maintain its beneficial effects.